Warrandyte, Australia

Jim Palmer

USPTO Granted Patents = 7 

Average Co-Inventor Count = 7.0

ph-index = 3

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
7 patents (USPTO):

Title: Jim Palmer: Innovator in Therapeutic Compounds

Introduction

Jim Palmer is a notable inventor based in Warrandyte, Australia. He has made significant contributions to the field of therapeutic compounds, holding a total of 7 patents. His work focuses on innovative solutions for treating various diseases, particularly those related to autoimmune and cancer conditions.

Latest Patents

Among his latest patents, Jim has developed inhibitors of the menin-MLL interaction. These patents disclose heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Specific inhibitors of this interaction are also described, along with pharmaceutical compositions that include these compounds. The methods of using these menin-MLL inhibitors are disclosed for the treatment of autoimmune diseases, heteroimmune diseases, and cancers such as lymphoma and leukemia. Another significant patent involves substituted pyridines as irreversible inhibitors of the menin-MLL interaction, further expanding the therapeutic options available for these conditions.

Career Highlights

Jim Palmer is currently associated with Biomea Fusion, Inc., where he continues to innovate in the field of therapeutic agents. His work has been instrumental in advancing the understanding and treatment of diseases that depend on menin-MLL interactions.

Collaborations

Jim collaborates with esteemed colleagues such as Thomas Butler and Ravi Upasani, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Jim Palmer's contributions to the field of therapeutic compounds highlight his dedication to improving treatment options for serious health conditions. His innovative patents and collaborative efforts position him as a key figure in the ongoing fight against diseases reliant on menin-MLL interactions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…